NBIP-'1968 / Neurocrine Biosciences - LARVOL DELTA

Neurocrine Biosciences…announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-’1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. (PRNewswire) - "The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese."

First-in-human • New P1 trial • Obesity